MedVentive revealed the names of two of the investors that took its over-subscribed Series C round to $10 million: Clarian Health Ventures and previous backer Core Capital Partners. The Waltham, Mass.-based healthcare information technology provider closed the C round in February, according to regulatory filings that, at the time, didn’t name the investors. But the […]
The company is in the midst of a Phase 2 trial on an ovarian drug that works with women who have developed resistance to chemotherapy. Data from the study will be available as early as mid-2010.
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
The Myriad is a minimally invasive surgical tool to remove all soft tumor tissue in the central nervous system. The company says it cuts procedure times and gives surgeons better control for difficult tissue shaving around critical areas in the body.